If yu gɛt Tayp 2 dayabitis, yu go dɔn ɔlrɛdi de tek mɛrɛsin lɛk Metformin. Bɔt yu dɔktɔ go dɔn tɛl yu bɔt wan nyu klas fɔ mɛrɛsin we dɛn kɔl SGLT2 inhibitors. Ɔ yu go dɔn yɛri bɔt dɛn. So, wetin na SGLT2 inhibito dεm? Aw dɛn kin rili wok? Insay dis atikul, wi go tɔk bɔt dɛn simpul wan ɛn kɔrɛkt wan.
Wetin na dɛn SGLT2 Inhibitors ya?
Fɔ tɔk am simpul wan, SGLT2 inhibitors na wan kayn ɔral pil we de ɛp fɔ kɔntrol yu blɔd shuga lɛvɛl. Di tin bɔt dɛn na dat dɛn kin wok difrɛn smɔl pas ɔda mɛrɛsin dɛn fɔ gɛt dayabitis.
Tink bɔt am, wi kidni na wɔndaful filta sistɛm. We wi de klin wi blɔd, di kidni dɛn de filta sɔm pan di shuga (glukɔs) we de na wi blɔd insay wi urine. כltu, wi kidni dεm gεt wan protin we dεn kכl Sodium-glucose cotransporter 2 , כ SGLT2 fכ sכt. lεk get-kipa, dis SGLT2 protin de kech mכst pan di shuga we de go insay di urine εn put am bak insay di bכdi.
Naw yu ɔndastand? Pɔsin we gɛt dayabitis dɔn ɔlrɛdi gɛt ay shuga na in blɔd. so wetin dεn SGLT2 inhibito dεm ya de du na fכ כf da get-kipa de, di SGLT2 protin, sכmtεm. Dɔn i nɔ kin ebul fɔ tek di shuga bak ɛn ad am to di blɔd. Dis kin mek di shuga we pasmak kin kɔmɔt na di bɔdi insay di urine . Dis na aw dɛn mɛrɛsin ya kin mek yu blɔd shuga go dɔŋ.
Dis kayn mɛrɛsin spɛshal bikɔs i de mek di blɔd shuga go dɔŋ difrɛn we, ɛn i nɔ de afɛkt di ɔmon insulin dairekt wan.
Wetin na di SGLT2 Inhibitors we kɔmɔn pas ɔl na Sri Lanka ɛn ɔda kɔntri dɛn?
Bɔku kayn mɛrɛsin dɛn de na dis grup. Dɛn ɔl de du di sem tin. Dɛn kin it dɛn wan tɛm insay di de, bifo di fɔs it fɔ di de. Yu dɔktɔ go chɛk yu sik ɛn gi yu di mɛrɛsin we fit yu pas ɔl.
| Jɛnɛrik nem fɔ di drɔg | Brand nem we dɛn kin yuz mɔ |
|---|---|
| Kanagliflɔzin we dɛn kɔl Kanagliflɔzin | Invokana we dɛn kɔl |
| Dapagliflɔzin we dɛn kɔl Dapagliflozin | Farxiga we de na di wɔl |
| Ɛmpagliflɔzin we dɛn kɔl Empagliflozin | Jardiance, we de na di wɔl |
| Ɛrtugliflɔzin we dɛn kɔl Ertugliflozin | Steglatro we nem Steglatro |
| Bexagliflozin we dɛn kɔl bexagliflozin | Brenzavvy bin de du am |
Udat fit fɔ yuz dis mɛrɛsin?
Dis na kwɛstyɔn we rili impɔtant. SGLT2 inhibitors nɔto di fɔs drɔg we dɔktɔ go gi fɔ Tayp 2 dayabitis.
Bɔku tɛm, dɔktɔ go advays fɔs fɔ chenj yu layf , lɛk fɔ kɔntrol di it dɛn we yu de it ɛn fɔ du ɛksɛsayz, dɔn i bigin fɔ tek mɛrɛsin lɛk Metformin.
Yu dɔktɔ kin tink bɔt wan SGLT2 inhibitor pan dɛn tin ya:
- Yu dɔn ɔlrɛdi de tek bɔku mɛrɛsin dɛn, bɔt dɛn stil nɔ ebul fɔ kɔntrol yu blɔd shuga fayn fayn wan .
- If yu gɛt mɛdikal rizin wae mek yu nɔr kin tek ɔda mɛrɛsin fɔ dayabitis.
- If yu de pan denja fɔ lɛ yu blɔd shuga nɔ bɔku (haypoglycemia).
- If yu nid fɔ lɛf fɔ it bɔku bɔku it ɔ fɔ mek yu blɔd prɛshɔn go dɔŋ.
Udat nɔ fɔ tek dis mɛrɛsin?
Dis kayn mɛrɛsin nɔr fayn fɔ ɔlman.
- Dɛn nɔ gri fɔ tek dis mɛrɛsin fɔ pipul dɛn we gɛt tayp 1 dayabitis .
- Dɛn nɔ kin fayn fɔ dɛn tin ya fɔ pipul dɛn we bin dɔn gɛt wan siriɔs prɔblɛm wit dayabitis we dɛn kɔl dayabitik ketoacidosis .
- Dis mɛrɛsin nɔ go bɛnifit pɔsin we dɔn ɔlrɛdi gɛt siriɔs kidni sik .
- If yu gɛt bɛlɛ, yu de tray fɔ gɛt bɛlɛ, ɔ yu de gi pikin in bɛlɛ, yu fɔ rili tɔk to yu dɔktɔ bɔt aw fɔ yuz dis mɛrɛsin. Nɔto inof data de bɔt in sef dis tɛm. So, nɔ bigin ɔ stɔp fɔ tek dis mɛrɛsin we yu nɔ go to dɔktɔ.
Wetin na di bad tin dɛn we kin apin to pɔsin?
Lɛk ɛni mɛrɛsin, dis mɛrɛsin kin mek sɔm bad bad tin dɛn apin. Bɔt, nɔto ɔlman kin gɛt dɛn. Ɛn dɛn kin ebul fɔ kɔntrol bɔku pan dɛn.
| Sayd ɛfɛkt we pɔsin kin gɛt | Diskripshɔn ɛn wetin fɔ no |
|---|---|
| Fɔ pis bɔku tɛm ɛn fɔ tɔsti | Bikɔs shuga kin kɔmɔt na di urine, yu kin nid fɔ pis bɔku tɛm ɔl di de ɛn nɛt. Dis kin mek bak yu tɔsti mɔ ɛn mɔ. Drink bɔku wata. |
| Urinary tract ɛn genital infɛkshɔn | Di shuga we de na di urine de mek di risk fɔ gɛt yist ɛn baktriyal infɛkshɔn. Tɛl yu dɔktɔ if yu gɛt sɔm sayn dɛn lɛk fɔ it, swel, ɔ pen na yu bɔdi. |
| We yu de lɔs yu wet | Yu kin lɔs sɔm wet bikɔs shuga (kalori) kin kɔmɔt na di urine. Dis na advantej fɔ sɔm pipul dɛn. |
| Lɔw blɔd prɛshɔn ɛn di wata we nɔ de na di bɔdi | Sɔntɛnde, as wata de kɔmɔt na di bɔdi, blɔd prɛshɔn kin go dɔŋ, we kin mek yu taya ɛn yu ed kin tɔn. |
| Wan siriɔs sayd ɛfɛkt we nid fɔ pe atɛnshɔn wantɛm wantɛm | |
| Dayabitik Kεtoasidכsis (DKA) . | Dis na tin we nɔ kin apin so ɔltɛm bɔt i kin rili denja . di bכdi de bכn fεt insted fכ shuga, we de mek asid dεm we dεn kכl kεtכn. If yu gɛt sɔm sayn dɛn lɛk nɔs, vɔmit, bɛlɛ pen bad bad wan, taya pasmak, ɛn i nɔ izi fɔ blo, tɛl yu dɔktɔ wantɛm wantɛm ɔ go na di ɔspitul imejensi rum (ETU) we de nia yu. |
Nɔto jɔs fɔ dayabitis, ɔda bɛnifit dɛn de!
Pan ɔl we dɛn bin mek dis mɛrɛsin fɔs fɔ mɛn dayabitis, risach dɔn sho se i gɛt bɔku ɔda wɔndaful bɛnifit dɛn.
1. Fɔ protɛkt di kidni dɛm: Dɛn mɛrɛsin ya kin ridyus di damej pan di kidni dɛm we dayabitis kin kam wit ɛn kɔntrol di prɔgrɛs we di kidni sik we nɔ de dɔn de go bifo.
2. Fɔ ridyus di risk fɔ gɛt at atak ɛn day bikɔs ɔf at atak: Dɛn dɔn sho se sɔm SGLT2 inhibitor dɛn kin ridyus di risk fɔ go na ɔspitul ɛn day, mɔ we dɛn gi dɛn to pipul dɛn we gɛt at prɔblɛm.
3. Fɔ ridyus di risk fɔ gɛt at atak ɛn strok: Sɔm stɔdi dɔn sho se dɛn tin ya kin ɛp bak fɔ ridyus di risk fɔ gɛt at atak ɛn strok.
Fɔ dɛn rizin ya, sɔntɛnde dɔktɔ dɛn kin gi dis mɛrɛsin to pipul dɛn we nɔ gɛt dayabitis bɔt we gɛt kidni sik ɔ at sik.
Mɛsej we dɛn kin kɛr go na os
- SGLT2 inhibito dεm na nyu klas כral mεdikeshכn dεm we de trit tayp 2 dayabεtis.
- Dɛn tin ya kin wok bay we dɛn kin stɔp di kidni dɛn fɔ mek dɛn nɔ tek di shuga bak insay di blɔd ɛn pul am na di urine.
- Dɛn nɔr kin bi di fɔs mɛrɛsin wae dɛn kin gi pɔrsin fɔ gɛt dayabitis. Yu dɔktɔ kin tɛl yu fɔ du dɛn tin ya we yu nɔ de kɔntrol yu blɔd shuga wit ɔda tritmɛnt dɛn.
- Apat frɔm we dɛn de kɔntrol dayabitis, dɛn gɛt di wɔndaful pawa bak fɔ protɛkt di kidni dɛn ɛn ridyus di risk fɔ gɛt at sik.
- Jɔs lɛk ɛni mɛrɛsin, sayd ɛfɛkt dɛn kin de. Tɔk to yu dɔktɔ bɔt ɛni chenj we yu gɛt.
- Na yu dɔktɔ nɔmɔ go disayd if dis mɛrɛsin fayn fɔ yu, so mek shɔ se yu tɔk bɔt dis wit am.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt